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HEMOSTASIS, THROMBOSIS,AND VASCULAR BIOLOGY
Transfer of tissue factor from leukocytes to platelets is mediated
by CD15 and tissue factor
Ursula Rauch, Diana Bonderman, Bernd Bohrmann, Juan J. Badimon, Jacques Himber, MarkusA. Riederer, and Yale Nemerson
We describe thrombogenic tissue factor
(TF) on leukocyte-derived microparticles
and their incorporation into spontaneous
human thrombi. Polymorphonuclear leu-
kocytes and monocytes transfer TF1
particles to platelets, thereby making
them capable of triggering and propagat-
ing thrombosis. This phenomenon calls
into question the original dogma that
vessel wall injury and exposure of TF
within the vasculature to blood is suffi-
cient for the occurrence of arterial throm-
bosis. The transfer of TF1 leukocyte-
derived particles is dependent on the
interaction of CD15 and TF with platelets.
Both the inhibition of TF transfer to
platelets by antagonizing the interaction
CD15 with P-selectin and the direct inter-
action of TF itself suggest a novel thera-
peutic approach to prevent thrombosis.
(Blood. 2000;96:170-175)
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Introduction
Vessel wall injury and exposure of tissue factor (TF) within the
vascular wall to blood are considered necessary for the initiation of
arterial thrombosis.1-3 This paradigm has been broadened by the
observation that TF is also present in circulating blood.4-6 We have
previously demonstrated the presence of TF in thrombi and have
shown that ex vivo thrombus and ﬁbrin formations were reduced by
the addition of a TF inhibitor to blood. These results indicate that
circulating TF is potentially active,4 which implies the existence of
a thrombogenic pool of circulating TF. In our study, TF in thrombi
appeared mostly on membranous structures that were proximate to
platelets. In fact, polymorphonuclear (PMN) leukocytes from both
circulating blood and rabbit liver tested positive for TF by
staining.4,7 In addition, leukocytes coincubated with platelets
generate more procoagulant activity than either cell type alone.8,9
Taken together, these data suggest that leukocytes are a potential
source of TF microparticles that adhere to platelets within a
thrombus. Leukocytes and platelets are known to interact via CD15
(aleukocytemembrane-boundcarbohydrateknownassialylLewisx)
with CD62P(P-selectin), which is an a granule–derived activation-
dependent adhesion molecule found on platelets.10-13
This study examines whether (1) a cell line that was derived
from monocytes (THP-1 cells) can transfer TF1 fragments to
platelets during thrombus formation and (2) the above-mentioned
adhesion molecules are involved in the formation of platelet-TF
hybrids. Furthermore, inhibitory monoclonal antibodies (mAbs) to
the identiﬁed membrane proteins were used to inhibit the transfer
of preexisting TF to platelets. Our data suggest that monocytes and
possibly PMN leukocytes are the source of circulating TF which is
transferred to platelets, thereby making F platelets capable of
triggering and propagating thrombosis. This transfer process is
mediated by the interaction of CD15 with platelets and byTF itself.
The inhibition of TF transfer to platelets suggests a novel therapeu-
tic approach to prevent thrombosis.
Materials and methods
Reagents
We used the following in this study: human recombinant factor VIIa
(FVIIa) (gift from Novo-Nordisk, Gentofte, Denmark); Spectrozyme Xa
(American Diagnostica, Greenwich, CT); monomeric bovine type I colla-
gen (Vitrogen; Collagen Corp, Palo Alto, CA); Tyrode’s solution, sterile
bovine serum albumin (BSA), citrate-dextrose solution (ACD), tumor
necrosis factor a (TNF-a), and prostaglandin E1 (Sigma Chemical Co, St
Louis, MO); Roswell Park Memorial Institute medium (RPMI 1640) with
L-glutamine, Hanks’ balanced salt solution (HBSS), phosphate-buffered
saline (PBS), and a penicillin-streptomycin combination (Gibco Life
Technologies, Braunschwedg, Germany); THP-1 cells (American Type
Culture Collection, Bethesda, MD); and DC Protein Assay (Bio-Rad
Laboratories, Hercules, CA). Puriﬁed factor X was prepared from human
plasma.14 Immunopuriﬁed rabbit antihuman TF polyclonal antibody
(pAb-TF) and digoxygenin-labeled FVIIa (Dig-VIIa) were prepared as
reported.15Anti-TF mAb (hTF1) has been described.16
Preparation of platelets and THP-1 cells
Platelet-rich plasma was prepared from citrated blood of healthy donors
(who had given informed consent) by centrifugation (Sorvall RT 6000B
Refrigerated Centrifuge; DuPont, Wilmington, Delaware) at 250g for 10
minutes. The plasma was mixed with modiﬁed Tyrode’s solution I
(Tyrode’s solution,ACD 1:10 vol/vol, 0.35% BSA[pH 6.5], and 20 µmol/L
prostaglandin E1). Isolated platelets were washed 2 times in modiﬁed
Tyrode’s solution II (Tyrode’s solution, 0.35% BSA[pH 6.5], and 20µmol/L
prostaglandin E1) followed by a ﬁnal washing in modiﬁed Tyrode’s
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170 BLOOD, 1 JULY 2000 x VOLUME 96, NUMBER 1solution III (Tyrode’s solution, 0.35% BSA, 2 mmol/Lmagnesium, and 100
U/mL penicillin/streptomycin). The platelet preparations were used for TF
transfer experiments after 30 minutes at rest. THP-1 cells from a human
monocytic cell line were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), L-glutamine, and 2% penicillin/streptomycin.
Before induction of TF, THP-1 cells were thoroughly washed in HBSS and
then incubated with 1 µg/mL TNF-a (cell concentration, 20 000 to 30 000
cells per µL) overnight.
Perfusion experiments on collagen- and platelet-coated
glass slides
Microscope slides (Superfrost/Plus, Fisher Scientiﬁc, Springﬁeld, NJ) were
incubated with 10 µg/mLcollagen overnight at 4 °C followed by washing 3
times in PBS and blocking in 1% BSA/PBS for 30 minutes. Perfusion
systems for the slides were previously reported.17 Two approaches for the
assessment of TF transfer to platelets were established: (1) Collagen-coated
glass slides were mounted in a parallel plate ﬂow chamber.17 The induced
THP-1 cells were mixed with platelets and perfused at a shear rate of 500s21
over collagen-coated slides. (2) A platelet carpet was ﬁrst deposited on the
collagen-coated slide by incubating isolated platelets in the presence of 1
mmol/L magnesium chloride and 2.5 mmol/L calcium chloride for 2 hours
at 37°C. The platelets deposited on collagen were then perfused with
TF-expressing THP-1 cells. All perfusions were performed for 10 minutes
at room temperature.
Immunocytochemistry
Immediately after perfusion, the slides were removed from the chamber,
gently rinsed in PBS, placed in freshly prepared 4% phosphate-buffered
paraformaldehyde (pH 7.4), and ﬁxed for 1 hour at room temperature.
The slides were washed in PBS, blocked with 1.2% peroxide in methanol
and goat serum, and incubated with 1 µg/mL anti-TF pAb (pAb-TF,
anti-sTF). Bound primary antibody was detected using a biotin streptavidin-
ampliﬁed detection system (BioGenex Laboratories, San Ramon, CA)
developed with 3,3-diaminobenzidine tetra-hydrochloride. After counter
staining with hematoxylin, the slides were examined microscopically.
Controls for immunostaining consisted of a nonspeciﬁc antibody as the
primary antibody.
Immunoelectron microscopy
Preembedding with double-immunogold labeling. Human blood was
perfused over collagen-coated slides to obtain thrombi as described.4 The
thrombi were then ﬁxed in 4% paraformaldehyde. Nonspeciﬁc binding was
reduced by washing the thrombi in 1.5% BSAand 0.5% ovalbumin in PBS
(pH 7.4) twice for 5 minutes each washing. Incubation with 10 µg/mLrabbit
anti-hTF pAb was performed in 0.1% BSA/PBS for 1 hour. Simultaneously,
we used 10 µg/mL anti-CD15 antibody (mouse monoclonal antineutrophil/
monocyte carbohydrate epitope, immunoglobulin M [IgM])(Dako, Hialeah,
FL). The samples were then washed 3 times in 0.1% BSA/PBS for 5
minutes each washing. The samples were incubated with secondary goat
antirabbit IgG coupled to 5-nm colloidal gold particles (Biocell Laborato-
ries, Rancho Dominguez, CA) or goat antimouse IgM coupled to 10-nm
colloidal gold particles. The samples were then diluted 1:40 in 0.1%
BSA/PBS and 0.05% Tween 20 (pH 7.4) for 1 hour.
Alternatively, primary and secondary antibodies were applied in a
single step and lead to identical results.After 3 washes in PBS for 5 minutes
each, the samples were ﬁxed in 2% glutaraldehyde in 0.1 mol/L sodium
cacodylate buffer (pH 7.4) for 1 hour, brieﬂy washed in 0.1 mol/L Na
cacodylate buffer, and postﬁxed in 2% osmium tetroxide.The samples were
then dehydrated in a series of aqueous ethanol solutions, exposed to
propylene oxide, and embedded in Epon 812 according to Luft.18 Ultrathin
sections were cut on a Reichert Ultracut S and stained with 5% aqueous
uranyl acetate followed by lead citrate.19 Electron micrographs were
acquired with a JEOL 1210 at 100 kV. The controls, which were treated
with mouse preimmune serum or nonspeciﬁc monoclonal IgG, revealed no
signiﬁcant stain, and a negligible background of fewer than 10 gold grains
was noted in cells greater than 10 µm2.
On-section immunogold labeling with ultrathin cryosections. Human
venous thrombi were obtained from a 38-year-old patient. Samples were
ﬁxed overnight with 4% formaldehyde in 0.1 mol/L PBS (pH 7.4). After
storage in PBS for 6 days, samples were dissected into small fragments not
more than 1 µL and postﬁxed in 3% formaldehyde with 0.1% glutaralde-
hyde in PBS for 2 hours. Sample preparation was done as described by
Tokuyasu20 with the following modiﬁcations: neutralization of free alde-
hydes was achieved by rinsing in PBS and incubating in 50 mmol/L
ammonium chloride in PBS for 1 hour. The samples were immersed
overnight in cryoprotection buffer consisting of 1.7 mol/Lsucrose and 15%
polyvinyl-pyrrolidone (10 000 MW) in 10 mmol/LPBS (pH 7.4) at 4°C and
frozen in liquid nitrogen.
Ultrathin (9-nm) cryosections were prepared at 2100°C with a Reichert
Ultracut S 1 FCS using a diamond knife (Diatome) in the presence of an
antistatic line (Diatome). Cryosections were collected in 2.3 mol/Laqueous
sucrose onto formvar/carbon–coated 200-mesh nickel grids. The sections
were thawed over PBS prior to immunolabeling, which was performed at
room temperature. The sections were ﬂoated on 0.05 mol/L glycine in PBS
for 15 minutes to inactivate free aldehyde groups and then on 2.5%
BSA/PBS and 2.5% ovalbumin for 15 minutes to block unspeciﬁc binding
sites. Sections were incubated with 10 µg/mL hTF1 in 2% BSA/PBS for 1
hour. After 6 washes in BSA/PBS, the sections were incubated with
secondary goat antimouse IgG (Amersham, Arlington Heights, IL), conju-
gated to 10-nm gold at 1:20 dilution in 2% BSAwith 0.1%Tween 20 in PBS
for 1 hour, and washed in BSA/PBS. For a control, we used sections treated
with normal mouse serum, which resulted in a negligible background of not
more than 10 gold grains in cells larger than 10 µm.2 The sections were
postﬁxed in 2% glutaraldehyde in PBS for 5 minutes, washed, and stained
with 0.4% uranyl acetate in 1.8% methyl cellulose (25 cP) for 5 minutes.
THP-1 cell–derived cell fragments and measurement
of TF activity
Conditioned medium from TNF-a–induced THP-1 cells was used as a
source of microparticles. THP-1 cells were removed by centrifugation at
2000g for 10 minutes, and the THP-1 cell pellet was washed in HBSS and
pelleted again. Cell particles and fragments present in the supernatant were
concentrated by centrifugation at 16 000g for 15 minutes. The absence of
THP-1 cells in the particle suspension was conﬁrmed by light microscopy.
The protein concentration of the particles was determined according to the
manufacturer’s instructions using a microplate protocol (DC ProteinAssay,
Bio-Rad Laboratories).Absorbance was read at 650 nm, and sample protein
concentrations were calculated from a standard curve using BSA. We
assayed 40 µL concentrated particles for TF activity using HEPES
(4-[2-Hydroxyethyl]-1-piperazineethanesulfonic acid) buffer with 1 nmol/L
FVIIa, 150 nmol/L factor X, and 5 mmol/L calcium chloride. At intervals,
samples were transferred to a microtiter plate in which each well contained
100 µL EDTA (ethylenediamine tetraacetic acid) buffer (50 mmol/L Bicine
[pH 8.5], 20 mmol/L EDTA, and 1 mg/mL BSA), which terminates
production of factor Xa. Chromogenic substrate Spectrozyme Xa (ﬁnal
concentration 0.5 mmol/L) was added to each well, and the increase in OD
was monitored at 405 nm for 10 minutes by using a kinetic enzyme-linked
immunoabsorbent assay (ELISA) plate reader at 35°C (Tmax, Molecular
Devices, Sunnyvale, CA). Activity was quantiﬁed by reference to puriﬁed
human rTF of known concentration.
Flow cytometry
Particles from TNF-a–induced THP-1 cells were freshly prepared and
resuspended in PBS for ﬂow cytometric analysis of surface membrane
proteins. Particles were blocked in normal goat serum and incubated with
an mAb to 20 µg/mLCD15 (cloneAHN1.1,Ancell), 10 µg/mLTF (hTF-1),
and 10 µg/mL CD18 (clone IB4, Ancell, Bayport, MN), respectively, for 2
hours at room temperature. Mouse IgG1 served as a control. After 2
washings in 1% BSA/PBS, samples were incubated with a secondary rabbit
antimouse antibody conjugated to phycoerythrin (PE) (Molecular Probes,
Eugene, OR) for 1 hour at room temperature. Flow cytometry was
performed immediately thereafter, and 10 000 events were acquired for
each measurement.
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the parallel ﬂow chamber was replaced by a cone and plate viscometer that
was suitable for small sample volumes (250 µL instead of 4 mL).21 Isolated
platelets were activated on collagen-coated glass plates within plastic wells;
TF-containing particles were added, and the mixture was subjected to
500s21 wall shear rates in the viscometer21 for 30 minutes. To examine
whether blocking antibodies to the identiﬁed adhesion proteins on the
microparticle surface inhibit the attachment of TF to platelets, TF-
containing microparticles were preincubated with either a blocking anti-
body to 200 µg/mL CD15 (anti-LewisX, clone AHN1.1, Ancell) or to 200
µg/mL TF (hTF-1) for 15 minutes at room temperature before adding the
microparticles to the platelets. After exposing the platelet-particle mixture
to shear stress, platelet-particle hybrids were ﬁxed in 1% paraformaldehyde
for 15 minutes, washed in PBS, incubated with 0.02% Triton X-100 in PBS
for 5 minutes at 37°C, and washed twice with PBS.
Platelet-particle hybrids were further blocked with 1% BSA/PSA and
normal goat serum, then stained with 1 µg/mL rabbit anti-TF pAb for 2
hours at room temperature or overnight at 4°C. After rinsing twice with
PBS, samples were incubated with a secondary goat antirabbit antibody
conjugated to PE. To double stain for TF and a speciﬁc platelet antigen on
platelet-particle hybrids, the sample was simultaneously incubated with 1
µg/mL mouse anti–platelet glycoprotein IIb/IIIa complex (anti-GPIIb/IIIa)
mAb (anti-CD41a,Ancell) directly conjugated to ﬂuorescein isothiocyanate
(FITC). Rabbit IgG, followed by the secondary antibody described above,
and mouse IgG-FITC were used as a negative staining control. The
incubation was performed at 4°C for 2 hours. Flow cytometry was
performed immediately thereafter.
Attachment of the TF-containing particles to platelets was inhibited by
hTF-1 (see ‘‘Results’’). To ensure that the mAb did not inhibit detection of
TF by the pAb, preliminary experiments binding pAb with and without the
addition of hTF-1 were performed. The presence of hTF-1 had no
signiﬁcant effect on the binding.
Confocal laser scanning microscopy
Platelet-TF hybrids were examined using a Leica TCS-SP (ultraviolet
[UV]) confocal laser scanning microscope (Leica, Heidelberg, Germany)
equipped with a 4-channel spectrophotometer scan head and 4 lasers
(argon-UV [Ar-UV], Ar, krypton, and helium-neon [HeNe]). For these
studies, the platelet-TF hybrids were illuminated simultaneously with the
l 488- and 568-nm laser lines. The pinhole size was adjusted such that
resultant ‘‘optical sections’’ were approximately 0.25- to 0.3-µm thick. To
ensurethatthesignaldidnot‘‘spillover’’fromonechannelintoanother,the
acousto-optical tunable ﬁlter was adjusted, and the spectrophotometer
windows in each channel were set so that signals from one channel were not
detected in the other channel.
Results
TF1 microparticles are transferred from leukocytes to platelets
To further visualize the structure of TF on platelets, immunoelec-
tronmicroscopy was performed on thrombi generated ex vivo by
perfusing human blood directly from a donor’s arm over collagen-
coated slides. TF1 pseudopodia extending from PMN leukocytes
were found to contact platelets within the thrombus (Figure 1).
Adhesion molecules present on the leukocyte surface, which may
possibly be involved in the adhesion to platelets during thrombus
formation, were also identiﬁed. A colocalization of CD15 and TF
on pseudopodia and small membrane particles was demonstrated
by double immunolabeling (Figure 1). To conﬁrm the presence of
TF1 particles within thrombi, a human venous thrombus obtained
from a patient was examined by immunoelectronmicroscopy. TF1
particles were present within the thrombus and also intermingled
with ﬁbrin strands (Figure 2).
THP-1 cells as a model to study the transfer of TF1 cell
fragments to platelets
We then established a perfusion model to study whether leukocytic
cells can transfer TF1 particles to platelets. Platelets isolated from
human blood were deposited on collagen-coated slides that were
then mounted in a parallel plate ﬂow chamber. THP-1 cells were
treated with TNF-a to induce the production of TF micropar-
ticles22,23; the suspension was then perfused at 500s21 over the
previously formed platelet carpet. In this model system, platelets,
which usually do not contain TF (Figure 3A), became TF1 after
being exposed to TF1 THP-1 cells and THP-1 cell–derived cell
fragments (Figure 3B).
Confocal microscopy demonstrated the colocalization of TF1
cell fragments and platelets. After coincubating activated platelets
with THP-1–derived TF particles overnight, platelet-particle hy-
brids were then stained forTF and CD41.TF fragments on platelets
were visualized by anti-TF pAbs that were detected with a secondary
antirabbit antibody conjugated to PE (Figure 4A), whereas the
platelets were recognized by FITC-conjugated anti-GPIIb (CD41)
antibodies (Figure 4B). Confocal microscopy revealed a high
degree of colocalization between TF and platelets (Figure 4C).
Identical results were obtained using an anti-TF mAb (not shown).
The TF cell fragments derived from stimulated THP-1 cells
were further characterized by qualitative and quantitative ﬂow
cytometric analysis. Conditioned medium from TNF-a–induced
THP-1 cells was used as a source of particles. CD15 and TF were
abundantly present on the microparticle surface (detectable in
approximately 60% and 45% of the particles, respectively; Figure
5A and 5B), whereas CD18 was only detectable in approximately
14% of the particles (Figure 5C). In addition, measurement of the
Xa generation by a chromogenic assay showed that THP-1
cell–derived fragments produced 370 pµ Xa per min in suspension,
which reﬂects the high procoagulant activity of leukocyte-derived
TF particles.
The role of CD15 and TF on the transfer of TF1 cell fragments
to platelets
At the platelet-PMN leukocyte contact site (Figure 1), an intense
cluster of TF and CD15 labeling was evident. This suggests a
Figure 1. Collagen-coated glass slides were perfused
with native human blood, and the deposited thrombi
were double immunostained for TF and CD15. (A)
Electronmicroscopy showing platelets and PMN leuko-
cytes within a thrombus. Note the PMN leukocyte–
derived membrane attached to the platelet surface de-
picted in the boxed ﬁeld. (B) Closeup examination of the
boxed ﬁeld: the structure double stains for CD15 (10-nm
gold grains) and TF (5-nm gold grains). (C) TF on small
particle-like structures in proximity to PMN leukocytes.
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particles from leukocytes to platelets. For these experiments we
employed a microcone and microplate viscometer using small
sample volumes of 250 µL.Anti-CD15 and anti-hTF (hTF-1) mAbs
reduced the formation of platelet-TF hybrids (Figure 6).
Discussion
The presence of thrombogenic TF activity in circulating blood has
recently been demonstrated by us,4 but the source of platelet-
associated TF and the mechanism of its transfer have not yet been
identiﬁed. In this study we present data indicating that monocytes
and possibly PMN leukoctyes were involved in the transfer of TF1
particles to platelets. Studies on THP-1 cells revealed that the
adherence of TF1 particles to platelets was mediated by CD15. The
role of P-selectin in thrombogenesis was previously shown in a
baboon model in which antibodies to P-selectin inhibited ﬁbrin
deposition in a polyester ﬁber arteriovenous shunt,24 although the
formation of TF-platelet hybrids was not considered. Moreover, it
has been shown that P-selectin knockout mice show a hemostatic
defect.25 The addition of anti-CD15 mAbs or oligosaccharides
containing sialyl Lewisx inhibits CD15 binding to P-selectin on
platelets. This action has been shown to prevent both platelet-
leukocyte adherence10,26,27 and the recurrence of arterial thrombosis
Figure 2. Ultrathin cryosections through a human venous thrombus. TF within
the thrombus was detected by on-section labeling using mAb anti-TF (hTF1) followed
by goat antimouse IgG conjugated to 10-nm colloidal gold. (A) Electronmicroscopy
shows TF1 cell fragments adjacent to the ﬁbrin strands. (B) Closeup of the region in
the boxed ﬁeld: a clearly discernible bilayered cell membrane and organelle
substructure are indicative of the cellular origin of the TF1 structures.
Figure 3. Results of immunocytochemistry performed on platelets. (A) The
platelets were isolated from circulating blood and deposited on collagen-coated
slides. Immunocytochemistry was performed to detect TF. When stained, the
platelets did not test positive for TF. Hemotoxylin was used for counter staining. (B)
THP-1 cells induced to produce TF and also TF1 microparticles by treatment with
TNF-a were perfused over a platelet carpet on a collagen-coated glass slide that was
mounted in a parallel plate ﬂow chamber.14 The induced THP-1 cells were perfused
over the platelets at 500s21. Note that platelets turned a brown color, indicating TF1,
after exposure to TF containing THP-1 cells (original magniﬁcation 3 200).
Figure 4. Platelets activated on collagen were incubated overnight with THP-1
cell–derived TF particles.The platelet-particle hybrids were then double stained:TF
particles on platelets were visualized by anti-TF pAb followed by staining with a
secondary goat antirabbit antibody conjugated to PE. The platelets were simulta-
neously stained by an FITC-conjugated mAb directed against GPIIb. (A) Confocal
microscopy reveals TF particles stained red. (B) GPIIb on platelets were stained
green. (C)An overlay of panelsAand B shows the colocalization of TF and platelets.
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explanation for these observations, namely that the CD15 and
P-selectin interactions mediate the formation of highly proco-
agulant platelet aggregates containing TF particles from leuko-
cytic cells.
Platelets becameTF1 after exposure toTF1 particles (Figure 3).
Our ﬁndings substantiate previous ex vivo observations suggesting
that leukocytes are one possible source of TF1 structures in
thrombi.4 Monocytes have been documented to express TF. Al-
though TF1 neutrophils have repeatedly been observed by us and
others, we do not know whether these cells synthesize TF. Further
studies are needed to evaluate whether PMN leukocytes acquire TF
from other cells and then deposit it onto platelet thrombi or whether
the leukocytes themselves are able to express TF.
Notably, it has been suggested that circulating microparticles
are a thrombogenic species.28,29 Previously it was shown that TF
modulates the migration of TF-containing monocytes through an
endothelial cell monolayer. Antibodies to TF and TF fragments
were inhibitory, thus implicating TF as an adhesive molecule
and suggesting the presence of a TF receptor on endothelial cells.30
A role for TF in cell adhesion and migration mediated by
interaction with intracellular actin-binding protein 280 was also
recently reported.31 Ultrastructural data on the location of TF
expressed by various cell lines demonstrated that TF was at the
cell surface and appeared in a spotty pattern at the base and apex
of budding processes and in close proximity to actin-rich regions.32
Immobilized ligands for TF accelerated the adhesion and spread-
ing of TF-expressing cells, which indicates that cellular TF may
be involved in cell adhesion.32 Taken together, these observations
implicate TF-leukocyte interactions in TF-dependent coagula-
tion and thrombotic events and support the concept of TF as an
adhesive molecule.
Suspensions of TF1 particles exhibited considerable TF activ-
ity, which points to the potential thrombogenicity of leukocyte-
derived TF-bearing particles. It should be emphasized that under
normal conditions, most cell surface TF is encrypted, which means
that the TF binds to FVIIa and anti-TF, but it is not capable of
initiating coagulation. Encrypted TF allows circulating TF1 leuko-
cytes to be present in the circulation without generalized coagula-
tion ensuing.33-36 The transfer of TF1 microparticles to platelets
during thrombogenesis clearly favors the propagation of thrombo-
sis. The activation of coagulation factors IX and X occurs very
close to platelet surfaces, thereby favoring the formation of factors
IXa:VIIIa and Xa:Va complexes on their highly procoagulant
surfaces. In our experiments, platelets seem to acquire TF after
thrombus formation has been initiated and therefore perpetuate the
process of thrombus growth. Whether platelet-associated TF may
be able to participate in the initiation of thrombus formation
remains to be clariﬁed.
Figure 5. Characterization of THP-1 cell–derived microparticles by ﬂow cytom-
etry. Using mAbs, we detected CD15, TF, and CD18 and acquired 10 000 events for
each measurement. Plots show the PE staining on particles (immunoﬂuorescence 2
[LFL-2]). Staining showed that (A) CD151 was present in 60% of the particles tested,
(B) TF was present in 45%, and (C) CD181 was present in 14%.
Figure 6. Inhibiting the transfer of TF cell fragments to platelets. Platelets were
activated on collagen, and (A) platelet-particle hybrids were double stained. TF was
visualized by rabbit pAbs against hTF followed by goat antirabbit antibodies
conjugated to PE, whereas platelets were stained with an FITC-conjugated mAb
directed against GPIIb. Plots in panels B, C, and D show the GPIIb1 particles
(platelets). (B) TF was found on 14% of platelets. (C) A blocking anti-CD15 antibody
inhibited the attachment of TF-containing particles to platelets. (D) The anti-TF mAb
(hTF-1) also reduced TF adherence to platelets.
174 RAUCH et al BLOOD, 1 JULY 2000 x VOLUME 96, NUMBER 1Our ﬁndings demonstrate thatTF1 microparticles are present on
platelets within thrombus-forming platelet-TF hybrids. Thus, the
data presented here show monocytes and possibly PMN leukocytes
as sources of TF1 membrane particles that are transferred to
platelets, thereby enabling them to trigger and propagate thrombo-
sis. The TF transfer process is mediated by the interaction of CD15
and TF with platelets, and the inhibition of TF transfer may be a
novel therapeutic approach to prevent thrombosis.
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